| Literature DB >> 26213249 |
Ehud Kaliner1, Eran Kopel2, Emilia Anis3, Ella Mendelson4, Jacob Moran-Gilad5, Lester M Shulman4, Shepherd R Singer6, Yossi Manor7, Eli Somekh8, Shmuel Rishpon9, Alex Leventhal10, Lisa Rubin11, Diana Tasher8, Mira Honovich1, Larisa Moerman6, Tamy Shohat12, Ravit Bassal12, Danit Sofer7, Michael Gdalevich13, Boaz Lev10, Ronni Gamzu14, Itamar Grotto5.
Abstract
In 2013, a silent wild poliovirus type 1 importation and sustained transmission event occurred in southern Israel. With the aim of preventing clinical poliomyelitis and ensuring virus re-elimination, the public health response to the importation event included intensification of clinical and environmental surveillance activities, enhancement of vaccine coverage, and supplemental immunisation with a bivalent oral polio vaccine against wild poliovirus types 1 and 3. A national campaign launched in August, 2013, resulted in vaccination of 943,587 children younger than 10 years (79% of the eligible target population). Expanded environmental surveillance (roughly 80% population coverage) documented a gradual disappearance of wild poliovirus type 1 in the country from September, 2013, to April, 2014. No paralytic poliomyelitis case was detected. A prompt extensive and coordinated national public health response, implemented on the basis of evidence-based decision making, successfully contained this serious importation and sustained transmission event of wild poliovirus to Israel. On April 28, 2015, WHO officially declared Israel as a polio-free country.Entities:
Mesh:
Year: 2015 PMID: 26213249 DOI: 10.1016/S1473-3099(15)00064-X
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071